Palbociclib plus letrozole versus placebo plus letrozole in Asian postmenopausal women with oestrogen receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer: Primary results from PALOMA-4-Reference-Cited by-同舟云学术

Palbociclib plus letrozole versus placebo plus letrozole in Asian postmenopausal women with oestrogen receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer: Primary results from PALOMA-4

Published:2022-11 Issue: Volume:175 Page:236-245
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Xu Binghe,Hu Xichun,Li Wei,Sun Tao,Shen Kunwei,Wang Shusen,Cheng Ying,Zhang Qingyuan,Cui Shude,Tong Zhongsheng,Geng Cuizhi,Song Erwei,Huang Chiun-Sheng,Sriuranpong Virote,Ngan Roger K.C.,Chia Yee H.,Wang Xinwei,Zhao Huadong

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference24 articles.

1. Contrasting epidemiology and clinicopathology of female breast cancer in Asians vs the US population;Lin;J Natl Cancer Inst,2019

2. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Sung;CA Cancer J Clin,2021

3. NCCN clinical Practice guidelines in Oncology (NCCN Guidelines®) breast cancer version 4.2021,2021

4. IBRANCE® capsules (palbociclib),2019

5. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study;Finn;Lancet Oncol,2015

Cited by 35 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Abemaciclib increases the risk of venous thromboembolism in breast cancer: Integrate meta-analysis, pharmacovigilance database analysis, and in vitro validation;Cancer Treatment Reviews;2024-11

2. Questionnaire survey and analysis of drug clinical research implementation capabilities of breast cancer treatment departments in Chinese hospitals;The Breast;2024-10

3. Palbociclib: Randomized Studies and Real-world Evidence as the Basis for Therapeutic Planning in Metastatic Breast Cancer;Geburtshilfe und Frauenheilkunde;2024-09

4. CDK4/6 inhibitors plus endocrine therapy vs. placebo plus endocrine therapy for HR+/HER2- advanced breast cancer: a phase III RCTs based meta-analysis;BMC Cancer;2024-08-21

5. Confirming the efficacy and safety of CDK4/6 inhibitors in the first-line treatment of HR+ advanced breast cancer: a systematic review and meta-analysis;Frontiers in Pharmacology;2024-08-05